PT - JOURNAL ARTICLE AU - Horton, Katherine C. AU - Richards, Alexandra S. AU - Emery, Jon C. AU - Esmail, Hanif AU - Houben, Rein M. G. J. TI - Re-evaluating progression and pathways following <em>Mycobacteria tuberculosis</em> infection within the spectrum of tuberculosis disease AID - 10.1101/2022.12.14.22283422 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.14.22283422 4099 - http://medrxiv.org/content/early/2022/12/14/2022.12.14.22283422.short 4100 - http://medrxiv.org/content/early/2022/12/14/2022.12.14.22283422.full AB - Background Traditional understanding of the risk of progression from Mycobacterium tuberculosis (Mtb) infection to tuberculosis (TB) disease overlooks nuance across a spectrum of disease.Methods We developed a deterministic model of Mtb infection and minimal (pathological damage but not infectious), subclinical (infectious but no reported symptoms), and clinical (infectious and symptomatic) TB disease, informed by a rigorous evaluation of data from a systematic review of TB natural history. Using a Bayesian approach, we calibrated the model to data from historical cohorts that followed tuberculin-negative individuals to tuberculin conversion and TB disease, as well as data from cohorts that followed progression and regression between disease states, disease state prevalence ratios, disease duration, and mortality. We estimated incidence, pathways, and ten-year outcomes following Mtb infection for a simulated cohort.Results 90.8% (95% uncertainty interval, UI, 90.2-91.3) of individuals self-cleared within 10 years of infection, while 9.3% (95% UI 8.4-10.0) progressed to TB disease. Of those, 68.1% (95% UI 65.1-71.1) developed infectious disease, and 32.7% (95% UI 29.7-35.7) progressed to clinical disease. While 93% of progression to minimal disease occurred within two years of infection, only 63% and 38% of subclinical and clinical disease, respectively, occurred within this period. Multiple progression pathways from infection were necessary to calibrate the model, and 48.8% (95% UI 45.0-52.6) of those who developed infectious disease undulated between disease states.Conclusions We identified highly heterogeneous pathways across disease states after Mtb infection, highlighting the need for clearly defined disease thresholds to inform more effective prevention and treatment efforts to end TB.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKCH, JCE, ASR, and RMGJH received funding from the European Research Council (ERC) under the European Union's Horizon 2020 programme (Starting Grant Action Number 757699). KCH and ASR are also supported by the UK FCDO (Leaving no-one behind: transforming gendered pathways to health for TB). HE acknowledges support from MRC (MR/V00476X/1). This research has been partially funded by UK aid from the UK government (to KCH and ASR); however the views expressed do not necessarily reflect the UK government's official policies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.